This product has not been evaluated by regulatory authorities for the diagnosis, treatment, cure, or prevention of any disease
Cerebrolysin's Position: Decades of clinical use across 40+ countries with established safety and efficacy data Meta-analyses and Cochrane systematic reviews the highest levels of clinical evidence Known limitations: complex mixture makes precise mechanism attribution difficult, not FDA-approved, requires IV/IM administration Represents validated but incrementally effective neurotrophic therapy Dihexa's Position: Exceptional mechanistic novelty HGF/c-Met potentiation at picomolar concentrations is a genuinely unique pharmacological finding if confirmed Entirely preclinical with no human data of any kind Foundational research compromised by expression of concern and retraction the core evidence base is actively questioned Theoretical safety concerns (c-Met oncogenesis) that have not been addressed experimentally Represents frontier neuroscience that has not survived the basic tests of scientific reproducibility For Researchers: Cerebrolysin offers a clinically validated tool for studying neurotrophic effects in humans, supported by the strongest available evidence
Managing blood sugar levels is crucial for preventing damage to the kidneys, eyes, nerves, and heart
Mothers who breastfeed and want to manage their weight often ask whether Wegovy and other GLP-1 receptor agonists are safe during lactation
Recent surveys indicate that approximately 8-12% of adults report using GLP-1 medications for weight loss or diabetes management, representing millions of Americans
